Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers
A Nationwide Population-Based Study

Yi-Chun Wang, MD, Tsung-Cheng Hsieh, PhD, Chu-Lin Chou, MD, PhD, Jung-Lun Wu, MS, and Te-Chao Fang, MD, PhD

Abstract: Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450 3A4 (CYP3A4). Inhibitors of CYP3A4 including some calcium channel blockers (CCBs) might increase statin blood concentration, owing to drug–drug interactions. Risk of adverse events such as acute kidney injury might occur following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.

This was a population-based cohort study. The study analyzed data of patients treated between 1997 and 2011, retrieved from Taiwan’s National Health Insurance database. We enrolled 32,801 patients who received coprescription of statins and CCBs that inhibit CYP3A4 (amlodipine, diltiazem, felodipine nicardipine, nifedipine, and verapamil). These patients were divided into 2 groups, according to whether they had received CYP3A4-metabolized statins (lovastatin, simvastatin, and atorvastatin) or non-CYP3A4-metabolized statins (fluvastatin, rosuvastatin, and pitavastatin). These 2 groups were 1:1 matched by age, gender, and Carlson comorbidity index. All outcomes were assessed within 90 days following drug coprescription.

In this study, 5857 patients received coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. There were no differences in comorbidity or use of antihypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted odds ratio [OR] = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic stroke (adjusted OR = 1.35; 95% CI = 1.08–1.68) than those who received non-CYP3A4-metabolized statins.

This nationwide cohort study demonstrated the increased risk of adverse events following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. Therefore, it is important to take into account the potential adverse events while coprescribing CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.

INTRODUCTION

Lipid-lowering drugs, particular statins, have been used worldwide to reduce the risk of cardiovascular events and death. Statin could be divided into 2 categories based on their metabolic pathway, cytochrome P450 3A4 (CYP3A4)-dependent and CYP3A4-independent. Based on pharmacokinetic characteristics, simvastatin, lovastatin, and atorvastatin are classified as CYP3A4-metabolized statins, while fluvastatin, rosuvastatin, and pitavastatin are non-CYP3A4-metabolized statins.1

Inhibitors of CYP3A4 could reduce presystemic metabolism of CYP3A4-metabolized statins and increase their plasma concentrations.1 Therefore, CYP3A4 inhibitors such as macrolide antibiotics frequently result in drug interactions with statins.1,2 It has been reported that coprescription of macrolide antibiotics with CYP3A4-metabolized statins increases the risk of statin toxicity, such as acute kidney injury and hyperkalemia.3 These effects were acute and could be observed within 30 days of coprescription.

Calcium channel blockers (CCBs) are one of the most popular drugs for hypertension. Certain CCBs, such as amiodipine, diltiazem, felodipine nicardipine, nifedipine, and verapamil, are relatively potent CYP3A4 inhibitors at clinically relevant dose.4 Drug–drug interactions could result after coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.

To the best of our knowledge, the potential risk of adverse events following the coprescription of statins and CCBs has been rarely reported. Therefore, we conducted a national, retrospective, and observational study to identify the adverse events after the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.

METHODS

Data Collection
Data of patients who received statins between January 1997 and December 2011 were obtained from Taiwan’s National Health Insurance database. We enrolled 32,801 patients who received coprescription of statins and CCBs that inhibit CYP3A4. There were no differences in comorbidity or use of antihypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted odds ratio [OR] = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic stroke (adjusted OR = 1.35; 95% CI = 1.08–1.68) than those who received non-CYP3A4-metabolized statins.

This nationwide cohort study demonstrated the increased risk of adverse events following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. Therefore, it is important to take into account the potential adverse events while coprescribing CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.
Longitudinal Health Insurance Database. The Longitudinal Health Insurance Database contains all of the registration files and details about the original claims that relates to 1 million beneficiaries from the National Health Insurance (NHI) database for research purposes. The NHI database holds information regarding outpatient data, inpatient data, disease profiles, the drugs prescribed, the intervention procedures, and the medical costs for more than 99% of the population in Taiwan, which equates to more than 22 million people. The diagnosis codes are based on the 9th revision of the International Classification of Diseases. To protect privacy, the individuals’ identifications are encrypted within the NHI database. This study was exempted from review by the Taipei Tzu Chi Hospital Review Board (IRB number: 03-W02-091).

Study Population

This was a population-based, longitudinal cohort study. Figure 1 illustrates the study subject selection process. Patients who received statins including lovastatin, simvastatin, atorvastatin fluvastatin, rosuvastatin, and pitavastatin for more than continuous 3 months between January 1997 and December 2011 were enrolled in the study. Patients who received more than one kind of statin, long-term renal replacement treatment, or kidney transplantation before receiving coprescription of statins and CCB which inhibit CYP3A4 were excluded from the study. Additionally, patients who never received coprescription of statins and CCB which inhibit CYP3A4 were excluded. Prescription of CCBs that inhibit CYP3A4 (amlodipine, diltiazem, felodipine nicardipine, nifedipine, and verapamil) within 30 days of receiving statin prescription was defined as coprescription. The patients who received coprescription of statin and CCBs were grouped according to whether they had received CYP3A4-metabolized statins (lovastatin, simvastatin, and atorvastatin) or non-CYP3A4-metabolized statins (fluvastatin, rosuvastatin, and pitavastatin). The 2 groups were 1:1 matched by age, gender, and Carlson comorbidity index. Baseline comorbidities were identified by ICD-9 codes, which included all cancers (140–172.9, 174–195.8), chronic kidney disease (582–582.9, 583–583.7, 585, 586, 588–588.9), coronary artery disease (414), diabetic mellitus (250–250.3, 250.7, 250.4–250.6), congestive heart failure (428–428.9), peripheral vascular disease (433.9, 411, 411.9, 785.4, V43.4), and cerebrovascular disease (430–437).

Measurements of Outcomes

All outcomes were assessed within 90 days after the coprescription of statin and CCBs. We used ICD 9 codes for identifying adverse events including acute kidney injury (584), hyperkalemia (276.7), acute liver failure (570), acute myocardial infarction (410), and acute ischemic stroke (433, 434, 436) after coprescription. Furthermore, we compared 90 days outcomes in a restricted cohort at 3 periods: 90 days prior to coprescription, 90 days after coprescription, and 91 to 180 days after coprescription.

Statistical Analysis

The patients’ baseline characteristics were compared using standardized difference, which has been used in previous studies. Standardized difference is less sensitive to sample size than traditional hypothesis test. They provided a measurement of the differences between groups divided by the pooled standard deviation. A value greater than 10% is interpreted as significant difference between the groups. In addition to the group effect, we adjusted for 13 potential confounding variables based on clinical relevance: age, sex, Charlson comorbidity score; baseline evidence of major cancers, renal disease, coronary artery disease, diabetic mellitus, congestive heart failure, peripheral vascular disease, cerebrovascular disease; baseline use of angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers, β-blockers, and diuretics. Univariate and multivariate logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for all outcomes. All variants with significant difference (P value <0.05) in univariate analysis were entered into the multivariate model. In outcomes analysis, P values lower than 0.05 were interpreted as statistically significant. All of the statistical analyses were performed using SAS version 9.3 for Windows (SAS Institute, Inc., Cary, NC).

RESULTS

In this study, 32,801 patients who received coprescription of statins and CCBs that inhibit CYP3A4 between January 1997 and December 2011 were enrolled. After grouping and matching, there were 5857 patients who received coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4 (Figure 1). There were no differences in comorbidity or anti-hypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins (Table 1).
Results of all the outcomes within 90 days after coprescription are presented in Table 2. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted OR = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic stroke (adjusted OR = 1.35; 95% CI = 1.08–1.68) than those who received non-CYP3A4-metabolized statins. However, risk of acute liver failure or mortality between these 2 groups did not reach statistical significance.

In this cohort, univariate and multivariate logistic regression model showed the relationships between adverse events and baseline characteristics (Table 3). These results demonstrated that coprescription of CYP3A4-metabolized statin and CCBs that inhibit CYP3A4 independently contributed to acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke.

Table 4 shows the risk of adverse events at different time periods, 90 days prior to coprescription and 91 to 180 days after coprescription of statin and CCBs. No significant differences of adverse events between CYP3A4-metabolized statins and non-CYP3A4-metabolized statins were observed at the time periods of either before or after coprescription of statins with CCBs that inhibit CYP3A4.

### DISCUSSION

The findings of our study demonstrated an increased risk of acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. To the best of our knowledge, this is the first population-based study to assess the adverse events of drug–drug interaction of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.

CYP3A4 is the one of the most abundant CYP enzyme in the liver and gut, and catalyzes the biotransformation of many drugs via oxidation. A number of important drugs have been identified as ‘‘substrates’’ or ‘‘inhibitors’’ of CYP3A4. In a prevalence study in Australia, potentially inappropriate CYP substrate–inhibitor interactions were reported in 6.2% of patients. The most commonly prescribed combinations that involved CYP3A4 were statins and CCBs. Therefore, we focused on the adverse events following the coprescription of statins (CYP3A4 substrate) and CCBs (CYP3A4 inhibitor) in our study.

Many in vitro studies have investigated the drug–drug interactions of statins and CCBs. Of the CCBs, verapamil and diltiazem could increase the area under the curve of simvastatin and lovastatin by 3- to 8-folds. As a consequence, it is reasonable to hypothesize the toxicity of statin after coprescription of CYP3A4-metabolized statins and CCBs (CYP3A4 inhibitor). In the present study, we did not compare the risk of adverse events of statins/CCBs versus stains alone, because this analysis would meet confounding by indication. Patients who received both statins and CCBs might be sicker than those who received stains alone. Therefore, we observed interaction risk by comparing CYP3A4-metabolized statins/CCBs against non-CYP3A4-metabolized statins/CCBs in the observational study.

Statin toxicity associated with drug interaction might involve renal, muscular, and hepatic adverse events. In a previous case report, rhabdomyolysis occurred following combined administration of CYP3A4-metabolized statins and diltiazem. Patel et al had reported that coprescription of CYP3A4-metabolized statins and CYP3A4 inhibitors increased

### TABLE 1. Baseline Characteristics

| Characteristics | CYP3A4-Metabolized Statins (Lovastatin, Simvastatin, Atorvastatin) N = 5857 | Non-CYP3A4-Metabolized Statins (Fluvastatin, Rosuvastatin, Pitavastatin) N = 5857 | Standard Difference*% |
|-----------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------|
| Age, mean (SD), year | 62.72 (12.64) | 62.72 (12.64) | <0.01 |
| Sex male, % | 3063 (52.30) | 3063 (52.30) | <0.01 |
| Charlson comorbidity index | 1952 (33.33) | 1952 (33.33) | <0.01 |
| <3 | 1848 (31.55) | 1849 (31.55) | <0.01 |
| >5 | 2057 (35.12) | 2056 (35.10) | <0.01 |
| Comorbid disorders | | | |
| Major cancers | 432 (7.38) | 407 (6.95) | 0.40 |
| Renal disease | 1036 (17.69) | 1265 (21.60) | 0.64 |
| Coronary artery disease | 2253 (38.47) | 2139 (36.52) | 1.12 |
| Diabetic mellitus | 2311 (39.46) | 2466 (42.10) | 1.13 |
| Congestive heart failure | 658 (11.23) | 631 (10.77) | 0.50 |
| Peripheral vascular disease | 39 (0.67) | 47 (0.80) | 0.11 |
| Cerebrovascular disease | 1690 (28.85) | 1509 (25.76) | 0.90 |
| Antihypertension drugs | | | |
| ACEI/ARB | 4530 (78.48) | 4392 (76.09) | 2.70 |
| B-blocker | 1285 (22.26) | 1264 (21.90) | 0.76 |
| Diuretic | 88 (1.52) | 93 (1.61) | 0.18 |

Data are n (%) or mean (standard deviation). ACEI = angiotensin-converting-enzyme inhibitors, ARB = angiotensin II receptor blockers, CYP3A4 = cytochrome P450 3A4, SD = standard deviation. Standardized difference provided a measurement of the difference between groups divided by the pooled standard deviation. They are less sensitive to sample size than traditional hypothesis test. A value greater than 10% is interpreted as significant difference between the groups.
### TABLE 2. Risk of Adverse Events Within 90 days After Coprescription of Statins and Calcium Channel Blockers

| Outcome                          | Number of Events, % | Odds Ratio (95% CI)          | Absolute Risk Difference, % |
|----------------------------------|---------------------|-----------------------------|----------------------------|
| Acute kidney injury              | 56 (0.96)           | 1.22 (0.76, 2.00)*          | 0.60 (0.36, 1.00)           |
| Hyperkalemia                     | 24 (0.41)           | 1.62 (0.93, 2.82)*          | 0.26 (0.14, 0.47)           |
| Acute myocardial infarction      | 12 (0.20)           | 1.30 (0.77, 2.25)*          | 0.07 (0.03, 0.18)           |
| Acute ischemic stroke            | 41 (0.70)           | 1.31 (0.81, 2.12)           |                            |
| Mortality                        | 56 (0.96)           | 1.44 (0.95, 2.18)*          |                            |

*P < 0.05.* CYP3A4-4 metabolized statins and CCBs inhibit CYP3A4, which leads to an increase in drug levels and a higher risk of adverse events. The results of this study suggest that physicians should be cautious when prescribing CYP3A4-metabolized statins and CCBs to patients at risk of adverse events.

The risk of rhabdomyolysis, acute kidney injury, and hyperkalemia was increased when CYP3A4-metabolized statins and CCBs were co-prescribed. The effects were observed in the group of CYP3A4-metabolized statins but not in the group of non-CYP3A4-metabolized statins. The results imply that the risk of adverse events is attributed to the coprescription of CYP3A4-metabolized statins and CCBs. Therefore, physicians should be cautious when prescribing these medications to patients at risk of adverse events.

In conclusion, the co-prescription of CYP3A4-metabolized statins and CCBs could increase the risk of adverse events. Physicians should be aware of this potential risk and consider alternative treatment options when possible.
**TABLE 3.** Univariate and Multivariate Logistic Regression Model Showing the Relationship between Risk of Adverse Events and Baseline Characteristics

| Characteristic              | Acute Kidney Injury Odds Ratio (95% CI) | Hyperkalemia Odds Ratio (95% CI) | Acute Myocardial Infarction Odds Ratio (95% CI) | Acute Ischemic Stroke Odds Ratio (95% CI) |
|-----------------------------|----------------------------------------|----------------------------------|-----------------------------------------------|------------------------------------------|
|                             | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate |
| Coprescription              | 1.94       | 2.12         | 2.67       | 2.94         | 1.56       | 1.55         | 1.34       | 1.35         |
|                             | (1.24, 3.04) | (1.35, 3.35) | (1.24, 5.76) | (1.36, 6.35) | (1.17, 2.08) | (1.16, 2.07) | (1.08, 1.67) | (1.08, 1.68) |
| Age                         | 1.04       |              | 1.05       | 1.02         | 1.03       |              | 1.02       |              |
|                             | (1.02, 1.06) |              | (1.02, 1.08) | (0.99, 1.05) | (1.02, 1.04) |              | (1.01, 1.03) |              |
| Sex                         | 1.18       |              | 0.86       |              | 2.36       |              | 1.27       |              |
|                             | (0.77, 1.82) |              | (0.43, 1.70) |              | (1.73, 3.22) |              | (1.02, 1.58) |              |
| Charlson comorbidity index  | 1.29       | 1.10         | 1.17       | 1.25         | 1.18       | 1.27         | (1.02, 1.58) |              |
|                             | (1.21, 1.38) | (1.01, 1.21) | (1.17, 1.44) |              | (1.13, 1.25) |              | (1.04, 1.61) |              |
| Major cancers               | 1.54       |              | 1.79       |              | 0.68       |              | 1.22       |              |
|                             | (0.77, 3.09) |              | (0.63, 5.11) |              | (0.36, 1.29) |              | (0.54, 1.33) |              |
| Renal disease               | 6.25       | 4.46         | 8.25       | 6.04         | 1.00       |              | 1.17       |              |
|                             | (4.04, 9.67) | (2.81, 7.07) | (4.00, 17.04) | (2.87, 12.71) | (0.70, 1.41) |              | (0.90, 1.52) |              |
| Coronary artery disease     | 1.17       |              | 0.95       |              | 6.23       |              | 0.80       |              |
|                             | (0.76, 1.80) |              | (0.47, 1.94) |              | (4.44, 8.76) |              | (0.63, 1.00) |              |
| Diabetic mellitus           | 2.19       | 1.51         | 2.55       | 1.88         | 0.86       |              | 1.09       |              |
|                             | (1.42, 3.39) | (0.96, 2.37) | (1.25, 5.18) | (0.91, 3.85) | (0.64, 1.15) |              | (0.87, 1.35) |              |
| Congestive heart failure    | 4.26       | 2.14         | 6.01       | 3.30         | 4.18       | 2.34         | 1.35       |              |
|                             | (2.71, 6.70) | (1.30, 3.52) | (3.01, 12.02) | (1.59, 6.86) | (3.09, 5.64) | (1.69, 3.23) | (0.99, 1.84) |              |
| Peripheral vascular disease | 3.31       |              | 0.68       |              |            |              | 1.64       |              |
|                             | (0.80, 13.69) |              | (0.09, 4.90) |              |            |              | (0.60, 4.51) |              |
| Cerebrovascular disease     | 2.27       | 1.42         | 1.97       |              | 0.87       |              |            |              |
|                             | (1.48, 3.49) | (0.88, 2.27) | (0.98, 3.92) |              | (0.09, 4.90) |              |            |              |
| ACEI/ARB                    | 3.28       | 1.68         | 9.40       | 4.68         | 4.26       | 2.93         | 1.32       |              |
|                             | (1.51, 7.12) | (0.76, 3.73) | (1.28, 68.81) | (0.63, 3.48) | (2.42, 7.48) | (1.66, 5.20) | (0.99, 1.74) |              |
| B-blocker                   | 1.23       |              | 0.095      |              | 1.12       |              | 0.69       |              |
|                             | (0.75, 2.00) |              | (0.41, 2.18) |              | (0.81, 1.55) |              | (0.51, 0.92) | (0.44, 0.80) |
| Diuretic                    | 5.64       | 2.66         | 3.97       |              | 2.27       | 1.31         | 0.91       |              |
|                             | (2.57, 12.40) | (1.16, 6.06) | (0.94, 16.69) |              | (1.05, 4.89) | (0.59, 2.88) | (0.37, 2.23) |              |

*p < 0.05. ACEI = angiotensin-converting-enzyme inhibitors, ARB = angiotensin II receptor blockers, CI = confidence interval.

Cerebrovascular disease was not enrolled in logistic regression model during acute ischemia stroke.
TABLE 4. Risk of Adverse Events at Other Time Periods: 90 Days Prior to Coprescription and 91 to 180 Days After Coprescription of Statins and Calcium Channel Blockers That Inhibit CYP3A4

| Outcome | 90 days prior to coprescription | 91 to 180 days after coprescription | Unadjusted | Adjusted * |
|---------|-------------------------------|------------------------------------|------------|-----------|
| Acute kidney injury | 17 (0.29) | 22 (0.38) | 0.12 | 0.09 |
| Hyperkalemia | 14 (0.24) | 12 (0.20) | 0.05 | 0.02 |
| Acute myocardial infarction | 34 (0.58) | 36 (0.61) | 0.03 | 0.01 |
| Acute ischemic stroke | 92 (1.57) | 76 (1.30) | 0.27 | 0.26 |

| Outcome | 90 days prior to coprescription | 91 to 180 days after coprescription | Unadjusted | Adjusted * |
|---------|-------------------------------|------------------------------------|------------|-----------|
| Acute kidney injury | 10 (0.17) | 17 (0.29) | 0.09 | 0.09 |
| Acute myocardial infarction | 14 (0.24) | 9 (0.15) | 0.05 | 0.01 |
| Acute ischemic stroke | 9 (0.15) | 8 (0.14) | 0.04 | 0.04 |

The present study has several limitations. First, we were unable to obtain information from the NIH database regarding the patients’ body height, body weight, and personal habits (physical activity, lifestyle, smoking, or alcohol consumption) in the NHRD database. Second, statins and CCBs blood levels after coprescription or other laboratory data were not available in this database. Third, this was an observational study; hence, we could not be entirely certain that these associations of adverse events could be attributed to inhibition of CYP3A4 metabolism. Finally, whether the findings from this study could apply to other racial is uncertain because the majority of population in this study is Chinese ethnicity.

Aside from its shortcomings, this study has some strengths. The data employed in this study was obtained from the NHI research database, which covers most inpatient and outpatient medical practices for Taiwan’s 23 million residents. It is one of the largest databases worldwide and has been used in many observational studies. In the present study, we compared CYP3A4-metabolized statins with non-CYP3A4-metabolized statins in order to minimize confounding by indication. In addition, we have minimized selection bias by matching control group with age, sex, and Charlson comorbidity score. Finally, we also verified that prescription of statins alone (90 days prior to coprescription) did not result in any statistically significant adverse events. This information reinforces the risk of coprescription of statins and CCBs.

In conclusion, our study found the associated risks of acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke were higher following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. Further, the risks were lower in the coprescription of non-CYP3A4-metabolized statins and CCBs. Therefore, clinicians could take into account the potential adverse events during the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.

ACKNOWLEDGMENTS

The authors thank National Health Research Institutes for providing us access to the National Health Insurance research database. The interpretations and conclusions contained herein do not represent National Health Research Institutes.

REFERENCES

1. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. *Clin Pharmacol Ther.* 2006;80:565–581.

2. Yang BR, Seong JM, Choi NK, et al. Co-medication of statins with contraindicated drugs. *PLoS One.* 2015;10:e0125180.

3. Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. *Ann Intern Med.* 2013;158:869–876.

4. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. *Ther Drug Monit.* 2007;29:687–710.

5. Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. *JAMA.* 2013;310:2544–2553.

6. Li DQ, Kim R, McArthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. *CMAJ.* 2015;187:174–180.
7. Mamdani M, Sykora K, Li P, et al. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330:960–962.

8. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41–57.

9. Kerr KP, Mate KE, Magin PJ, et al. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. J Clin Pharm Ther. 2014;39:383–389.

10. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998;64:369–377.

11. Jasinska M, Owczarek J, Orszulak-Michalak D. The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study. Acta Pol Pharm. 2006;63:386–390.

12. Watanabe H, Kosuge K, Nishio S, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 2004;76:281–292.

13. Marumo H, Satoh K, Yamamoto A, et al. Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakugaku Zasshi. 2001;121:761–764.

14. Lewis JJ3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002;36:1546–1549.

15. Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21:494–506.

16. Moura CS, Prado NM, Belo NO, et al. Evaluation of drug-drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm. 2012;34:547–552.

17. Andersson ML, Bottiger Y, Lindh JD, et al. Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care. Eur J Clin Pharmacol. 2013;69:565–571.

18. Menda ML, Waikar SS. Drug-drug interactions and acute kidney injury: caveat prescriber. Am J Kidney Dis. 2014;64:492–494.

19. Chou CL, Hsieh TC, Wang CH, et al. Long-term outcomes of dialysis patients after coronary revascularization: a population-based cohort study in Taiwan. Arch Med Res. 2014;45:188–194.

20. Chen YC, Hwang SJ, Li CY, et al. A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Medicine (Baltimore). 2015;94:e1334.

21. Chang YK, Liu JS, Hsu YH, et al. Increased risk of end-stage renal disease (ESRD) requiring chronic dialysis is associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs): nationwide case-crossover study. Medicine (Baltimore). 2015;94:e1362.

22. Huang HS, Hsu CC, Weng SF, et al. Acute anticholinesterase pesticide poisoning caused a long-term mortality increase: a nationwide population-based cohort study. Medicine (Baltimore). 2015;94:e1222.

23. Hung SC, Chang YK, Liu JS, et al. Mortality and metformin use in patients with advanced chronic kidney disease – Authors’ reply. Lancet Diabetes Endocrinol. 2015;3:681.

24. Lin HF, Li YH, Wang CH, et al. Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transplant. 2012;27:1585–1590.

25. Hung TH, Chou CL, Fang TC. Impact of renal dysfunction in cirrhotic patients with bacterial infections other than spontaneous bacterial peritonitis. Hepatol Res. 2014;44:863–870.

26. Kuo CH, Hsieh TC, Wang CH, et al. Increased risks of mortality and atherosclerotic complications in incident hemodialysis patients subsequently with bone fractures: a nationwide case-matched cohort study. PLoS One. 2015;10:e0121705.